{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:29:47Z","timestamp":1790688587072,"version":"4.1.0"},"reference-count":413,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013511","name":"Silm\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013511","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008376","name":"Helsingin ja Uudenmaan Sairaanhoitopiiri","doi-asserted-by":"publisher","award":["2020315"],"award-info":[{"award-number":["2020315"]}],"id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008723","name":"Suomen L\u00e4\u00e4ketieteen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015738","name":"Mary och Georg C Ehrnrooths stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011905","name":"Evald ja Hilda Nissin S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011905","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013510","name":"Silm\u00e4- ja kudospankkis\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004334","name":"Etela Pohjanmaa Hospital District","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010810","name":"\u00d6gonfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010810","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Retinal and Eye Research"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.preteyeres.2022.101041","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T11:44:38Z","timestamp":1641469478000},"page":"101041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":165,"special_numbering":"C","title":["Metastatic uveal melanoma: The final frontier"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5025-4269","authenticated-orcid":false,"given":"Elina S.","family":"Rantala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela M.","family":"Hernberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Piperno-Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans E.","family":"Grossniklaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1198-4394","authenticated-orcid":false,"given":"Tero T.","family":"Kivel\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.preteyeres.2022.101041_bib1","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1159\/000508382","article-title":"Gene expression profiling in uveal melanoma: five-year prospective outcomes and meta-analysis","volume":"6","author":"Aaberg","year":"2020","journal-title":"Ocul. Oncol. Pathol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib2","series-title":"Survival and Event History Analysis: a Process Point of View","author":"Aalen","year":"2008"},{"key":"10.1016\/j.preteyeres.2022.101041_bib3","first-page":"313","article-title":"Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma","volume":"42","author":"Aalto","year":"2001","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2022.101041_bib4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.exer.2012.04.010","article-title":"Monosomy 3 status of uveal melanoma metastases is associated with rapidly progressive tumors and short survival","volume":"100","author":"Abdel-Rahman","year":"2012","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib5","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1755-3768.1983.tb04350.x","article-title":"Malignant melanoma of the choroid and the ciliary body 1956-1975 in Halland and Gothenburg. Incidence, histopathology and prognosis","volume":"61","author":"Abrahamsson","year":"1983","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib6","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jclinepi.2013.06.009","article-title":"Reporting quality of survival analyses in medical journals still needs improvement. A minimal requirements proposal","volume":"66","author":"Abraira","year":"2013","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib7","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.molimm.2013.11.018","article-title":"Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease","volume":"58","author":"Achberger","year":"2014","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000485189","article-title":"The patient's experience of ocular melanoma in the US: a survey of the Ocular Melanoma Foundation","volume":"4","author":"Afshar","year":"2018","journal-title":"Ocul. Oncol. Pathol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/01.cmr.0000129377.22141.ea","article-title":"Phase I\/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver","volume":"14","author":"Agarwala","year":"2004","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib10","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1126\/science.aav0191","article-title":"How dormant cancer persists and reawakens","volume":"361","author":"Aguirre-Ghiso","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.preteyeres.2022.101041_bib11","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaophthalmol.2014.5395","article-title":"International validation of the American Joint Committee on Cancer's 7th edition classification of uveal melanoma","volume":"133","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2022.101041_bib12","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.ophtha.2015.12.024","article-title":"The pediatric choroidal and ciliary body melanoma study: a survey by the European ophthalmic oncology group","volume":"123","author":"Al-Jamal","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib13","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1755-3768.2009.01556.x","article-title":"Nucleolar size in choroidal and ciliary body melanomas and corresponding hepatic metastases","volume":"88","author":"Al-Jamal","year":"2010","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/archopht.1996.01100130103030","article-title":"Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis","volume":"114","author":"Albert","year":"1996","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib15","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1634\/theoncologist.5-5-416","article-title":"Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver","volume":"5","author":"Alexander","year":"2000","journal-title":"Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib16","first-page":"6343","article-title":"Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver","volume":"9","author":"Alexander","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib17","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1002\/cncr.30258","article-title":"Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies","volume":"122","author":"Algazi","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/bjc.1995.364","article-title":"Review of survival analyses published in cancer journals","volume":"72","author":"Altman","year":"1995","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib19","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3390\/cancers11060856","article-title":"Pilot study of circulating tumor cells in early-stage and metastatic uveal melanoma","volume":"11","author":"Anand","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.preteyeres.2022.101041_bib20","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/1097-0142(20001001)89:7<1561::AID-CNCR21>3.0.CO;2-R","article-title":"Protracted survival after resection of metastatic uveal melanoma","volume":"89","author":"Aoyama","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000480640","article-title":"Uveal Melanoma: 5-year update on incidence, treatment, and survival (SEER 1973-2013)","volume":"4","author":"Aronow","year":"2018","journal-title":"Ocul. Oncol. Pathol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40644-019-0218-4","article-title":"Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience","volume":"19","author":"Artzner","year":"2019","journal-title":"Cancer Imag."},{"key":"10.1016\/j.preteyeres.2022.101041_bib23","first-page":"128","article-title":"Quality of evidence about effectiveness of treatments for metastatic uveal melanoma","volume":"106","author":"Augsburger","year":"2008","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"10.1016\/j.preteyeres.2022.101041_bib24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ajo.2009.01.023","article-title":"Effectiveness of treatments for metastatic uveal melanoma","volume":"148","author":"Augsburger","year":"2009","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ajo.2011.03.004","article-title":"Surveillance testing for metastasis from primary uveal melanoma and effect on patient survival","volume":"152","author":"Augsburger","year":"2011","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib26","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S0161-6420(84)34088-X","article-title":"Growth rates and doubling times of posterior uveal melanomas","volume":"91","author":"Augsburger","year":"1984","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib27","first-page":"3993","article-title":"Development of a technic for isolated perfusion of the liver","volume":"61","author":"Ausman","year":"1961","journal-title":"N. Y. State J. Med."},{"key":"10.1016\/j.preteyeres.2022.101041_bib28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000503035","article-title":"Symptomatic liver metastasis prompting diagnosis of uveal melanoma","volume":"6","author":"Awh","year":"2020","journal-title":"Ocul. Oncol. Pathol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib29","first-page":"1011","article-title":"Lineage infidelity and expression of melanocytic markers in human breast cancer","volume":"33","author":"Bachmeier","year":"2008","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib30","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1167\/iovs.14-15571","article-title":"The prognostic effect of American Joint Committee on Cancer staging and genetic status in patients with choroidal and ciliary body melanoma","volume":"56","author":"Bagger","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2022.101041_bib31","doi-asserted-by":"crossref","first-page":"20160092","DOI":"10.1259\/bjr.20160092","article-title":"Imaging of ocular melanoma metastasis","volume":"89","author":"Balasubramanya","year":"2016","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib32","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1007\/s00270-016-1336-z","article-title":"Stereotactic radiofrequency ablation for metastatic melanoma to the liver","volume":"39","author":"Bale","year":"2016","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib33","first-page":"1897","article-title":"Serum markers to detect metastatic uveal melanoma","volume":"27","author":"Barak","year":"2007","journal-title":"Anticancer Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib34","first-page":"345","article-title":"The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1)","volume":"31","author":"Barak","year":"2011","journal-title":"Anticancer Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib35","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3109\/02713683.2010.534573","article-title":"VEGF as a biomarker for metastatic uveal melanoma in humans","volume":"36","author":"Barak","year":"2011","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib36","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1001\/jamaophthalmol.2015.1766","article-title":"Potential role of soluble c-Met as a new candidate biomarker of metastatic uveal melanoma","volume":"133","author":"Barisione","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2022.101041_bib37","doi-asserted-by":"crossref","first-page":"646","DOI":"10.6004\/jnccn.2018.0042","article-title":"New NCCN guidelines for uveal melanoma and treatment of recurrent or progressive distant metastatic melanoma","volume":"16","author":"Barker","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.preteyeres.2022.101041_bib38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/cjp2.105","article-title":"Replacement and desmoplastic histopathological growth patterns: a pilot study of prediction of outcome in patients with uveal melanoma liver metastases","volume":"4","author":"Barnhill","year":"2018","journal-title":"J Pathol Clin Res"},{"key":"10.1016\/j.preteyeres.2022.101041_bib39","article-title":"Clinical application of circulating tumor cells and circulating tumor DNA in uveal melanoma","volume":"2","author":"Beasley","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.preteyeres.2022.101041_bib40","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/sj.bjc.6600521","article-title":"Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2","volume":"87","author":"Becker","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib41","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/1097-0142(19951101)76:9<1665::AID-CNCR2820760925>3.0.CO;2-J","article-title":"Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors","volume":"76","author":"Bedikian","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib42","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/02656736.2017.1286046","article-title":"The effect of perfusate buffering on toxicity and response in isolated hepatic perfusion for uveal melanoma liver metastases","volume":"33","author":"Ben-Shabat","year":"2017","journal-title":"Int. J. Hyperther."},{"key":"10.1016\/j.preteyeres.2022.101041_bib43","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1245\/s10434-015-4982-5","article-title":"Long-term follow-up evaluation of 68 patients with uveal melanoma liver metastases treated with isolated hepatic perfusion","volume":"23","author":"Ben-Shabat","year":"2016","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib44","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1167\/iovs.03-0081","article-title":"Uveal melanoma survival in Sweden from 1960 to 1998","volume":"44","author":"Bergman","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2022.101041_bib45","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/IAE.0000000000002385","article-title":"Correlation of gene expression profile status and American Joint Commission on Cancer stage in uveal melanoma","volume":"40","author":"Berry","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2022.101041_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048787","article-title":"Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: swog S0512","volume":"7","author":"Bhatia","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.preteyeres.2022.101041_bib47","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/ijc.28436","article-title":"Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma","volume":"134","author":"Bidard","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib48","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/S1470-2045(15)00396-4","article-title":"Research methods to change clinical practice for patients with rare cancers","volume":"17","author":"Billingham","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib49","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1136\/bjophthalmol-2019-314461","article-title":"A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes","volume":"104","author":"Binkley","year":"2020","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib50","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/CMR.0b013e328357bea8","article-title":"Uveal melanoma dormancy: an acceptable clinical endpoint?","volume":"22","author":"Blanco","year":"2012","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib51","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/S1470-2045(15)00388-5","article-title":"The value of research collaborations and consortia in rare cancers","volume":"17","author":"Blay","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib52","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3390\/cancers11101489","article-title":"Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma","volume":"11","author":"Bol","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.preteyeres.2022.101041_bib53","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ajo.2014.07.014","article-title":"Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients","volume":"158","author":"Bol","year":"2014","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib54","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.ophtha.2016.06.027","article-title":"Adjuvant dendritic cell vaccination in high-risk uveal melanoma","volume":"123","author":"Bol","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib55","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/ajcp\/92.4.491","article-title":"Breast carcinoma with positive results for melanoma marker (HMB-45). HMB-45 immunoreactivity in normal and neoplastic breast","volume":"92","author":"Bonetti","year":"1989","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib56","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/jso.24984","article-title":"Hepatic artery infusion of melphalan in patients with liver metastases from ocular melanoma","volume":"117","author":"Boone","year":"2018","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib57","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/jcp.2010.087999","article-title":"The biology of micrometastases from uveal melanoma","volume":"64","author":"Borthwick","year":"2011","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib58","series-title":"DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology","first-page":"502","article-title":"Assessment of clinical response","author":"Brawley","year":"2019"},{"key":"10.1016\/j.preteyeres.2022.101041_bib59","series-title":"DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology","first-page":"454","article-title":"Cancer screening","author":"Brawley","year":"2019"},{"key":"10.1016\/j.preteyeres.2022.101041_bib60","first-page":"5672048","article-title":"Unresectable hepatic metastasis of uveal melanoma: hepatic chemosaturation with high-dose melphalan-long-term overall survival negatively correlates with tumor burden","volume":"2020","author":"Br\u00fcning","year":"2020","journal-title":"Radiol. Res. Pract."},{"key":"10.1016\/j.preteyeres.2022.101041_bib61","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00270-015-1276-z","article-title":"Percutaneous isolated hepatic perfusion for the treatment of unresectable liver malignancies","volume":"39","author":"Burgmans","year":"2016","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib62","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2174\/1874364101206010049","article-title":"Long-term survivors with metastatic uveal melanoma","volume":"6","author":"Buzzacco","year":"2012","journal-title":"Open Ophthalmol. J."},{"key":"10.1016\/j.preteyeres.2022.101041_bib63","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/sj.eye.6702322","article-title":"Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study","volume":"21","author":"Callejo","year":"2007","journal-title":"Eye"},{"key":"10.1016\/j.preteyeres.2022.101041_bib64","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/030089169408000107","article-title":"Intra-arterial hepatic carboplatin-based chemotherapy for ocular melanoma metastatic to the liver. Report of a phase II study","volume":"80","author":"Cantore","year":"1994","journal-title":"Tumori"},{"key":"10.1016\/j.preteyeres.2022.101041_bib65","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1007\/s00270-015-1093-4","article-title":"Transarterial chemoembolization of liver metastases from uveal melanoma using irinotecan-loaded beads: treatment response and complications","volume":"38","author":"Carling","year":"2015","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib66","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2017.74.1090","article-title":"Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicenter, randomized trial (SUMIT)","volume":"36","author":"Carvajal","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib67","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","article-title":"Metastatic disease from uveal melanoma: treatment options and future prospects","volume":"101","author":"Carvajal","year":"2017","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib68","author":"Chadha"},{"key":"10.1016\/j.preteyeres.2022.101041_bib69","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1470-2045(17)30251-6","article-title":"Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study","volume":"18","author":"Chandran","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib70","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0002-9394(78)90018-1","article-title":"Metastatic choroidal melanoma","volume":"86","author":"Char","year":"1978","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib71","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/archopht.1997.01100160184007","article-title":"Uveal melanoma. Growth rate and prognosis","volume":"115","author":"Char","year":"1997","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib72","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00432-014-1804-2","article-title":"DJ-1: a promising marker in metastatic uveal melanoma","volume":"141","author":"Chen","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib73","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1093\/annonc\/mdg379","article-title":"ESMO takes a stand on supportive and palliative care","volume":"14","author":"Cherny","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib74","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/jamaophthalmol.2015.4810","article-title":"Hepatic ultrasonography for surveillance in patients with uveal melanoma","volume":"134","author":"Choudhary","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2022.101041_bib75","first-page":"2071","article-title":"Inter-rater reliability in performance status assessment among healthcare professionals: an updated systematic review and meta-analysis","volume":"28","author":"Chow","year":"2020","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib76","first-page":"1422","article-title":"Lack of lymphangiogenesis despite coexpression of VEGF-C and its receptor Flt-4 in uveal melanoma","volume":"42","author":"Clarijs","year":"2001","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2022.101041_bib77","first-page":"988","article-title":"Observations on growth rates of human tumors","volume":"76","author":"Collins","year":"1956","journal-title":"Am. J. Roentgenol. Radium Ther. Nucl. Med."},{"key":"10.1016\/j.preteyeres.2022.101041_bib78","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/sj.bjc.6602586","article-title":"Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients","volume":"92","author":"Corrie","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib79","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3390\/cancers11060846","article-title":"Targeted therapy of uveal melanoma: recent failures and new perspectives","volume":"11","author":"Croce","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.preteyeres.2022.101041_bib80","first-page":"5761","article-title":"Absence of BRAF and NRAS mutations in uveal melanoma","volume":"63","author":"Cruz","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib81","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.preteyeres.2018.03.004","article-title":"Ocular treatment of choroidal melanoma in relation to the prevention of metastatic death - a personal view","volume":"66","author":"Damato","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib82","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1158\/1078-0432.CCR-10-2076","article-title":"Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification","volume":"16","author":"Damato","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib83","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.preteyeres.2011.05.003","article-title":"Estimating prognosis for survival after treatment of choroidal melanoma","volume":"30","author":"Damato","year":"2011","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib84","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00262-011-1089-0","article-title":"Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy","volume":"61","author":"Danielli","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.preteyeres.2022.101041_bib85","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/bjc.2016.419","article-title":"Phase II randomised discontinuation trial of the MET\/VEGF receptor inhibitor cabozantinib in metastatic melanoma","volume":"116","author":"Daud","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib86","first-page":"1868","article-title":"Risk-stratified systemic surveillance in uveal melanoma","volume":"103","author":"Davanzo","year":"2019","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib87","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1001\/archophthalmol.2009.45","article-title":"Hepatic metastasis from uveal melanoma: angiographic pattern predictive of survival after hepatic arterial chemoembolization","volume":"127","author":"Dayani","year":"2009","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib88","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/CMR.0000000000000286","article-title":"Isolated (hypoxic) hepatic perfusion with high-dose chemotherapy in patients with unresectable liver metastases of uveal melanoma: results from two experienced centres","volume":"26","author":"de Leede","year":"2016","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib89","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djaa047","article-title":"Germline MBD4 mutations and predisposition to uveal melanoma","volume":"113","author":"Derrien","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.preteyeres.2022.101041_bib90","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1200\/JCO.2004.08.194","article-title":"Screening for metastasis from choroidal melanoma: the collaborative ocular melanoma study group report 23","volume":"22","author":"Diener-West","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib91","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/archopht.123.12.1639","article-title":"Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative Ocular Melanoma Study Group Report No. 26","volume":"123","author":"Diener-West","year":"2005","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib92","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/00006982-200001000-00014","article-title":"Intraocular melanoma spread to regional lymph nodes: report of two cases","volume":"20","author":"Dithmar","year":"2000","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2022.101041_bib93","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1167\/iovs.16-20212","article-title":"The prognostic value of AJCC Staging in uveal melanoma is enhanced by adding chromosome 3 and 8q status","volume":"58","author":"Dogrus\u00f6z","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2022.101041_bib94","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/aos.13580","article-title":"Genetic prognostication in uveal melanoma","volume":"96","author":"Dogrus\u00f6z","year":"2018","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib95","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1158\/1078-0432.CCR-18-1368","article-title":"Arylsulfonamide 64B inhibits hypoxia\/HIF-Induced expression of c-Met and CXCR4 and reduces primary tumor growth and metastasis of uveal melanoma","volume":"25","author":"Dong","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib96","doi-asserted-by":"crossref","first-page":"335","DOI":"10.7863\/jum.2003.22.4.335","article-title":"Utility of sonography for small hepatic lesions found on computed tomography in patients with cancer","volume":"22","author":"Eberhardt","year":"2003","journal-title":"J. Ultrasound Med."},{"key":"10.1016\/j.preteyeres.2022.101041_bib97","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.2214\/AJR.11.7748","article-title":"Fotemustine chemoembolization of hepatic metastases from uveal melanoma: a retrospective single-center analysis","volume":"199","author":"Edelhauser","year":"2012","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib98","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/PL00012075","article-title":"Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients","volume":"6","author":"Egerer","year":"2001","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib99","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1111\/jdv.12405","article-title":"MR-guided laser-induced thermotherapy (LITT) in patients with liver metastases of uveal melanoma","volume":"28","author":"Eichler","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/aos.12462","article-title":"Immunomagnetic detection of micrometastatic cells in bone marrow of uveal melanoma patients: a paradox","volume":"93","author":"Eide","year":"2015","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib101","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12253-017-0355-7","article-title":"The results of stricter inclusion criteria in an immunomagnetic detection study of micrometastatic cells in bone marrow of uveal melanoma patients - relevance for dormancy","volume":"25","author":"Eide","year":"2019","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib102","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/1097-0142(197410)34:4<1001::AID-CNCR2820340406>3.0.CO;2-Z","article-title":"Metastatic patterns of choroidal melanoma","volume":"34","author":"Einhorn","year":"1974","journal-title":"Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib103","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib104","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1167\/iovs.09-4739","article-title":"Regulation of VEGF-A in uveal melanoma","volume":"51","author":"el Filali","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2022.101041_bib105","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1186\/1471-2407-14-962","article-title":"MicroRNA in exosomes isolated directly from the liver circulation in patients with metastatic uveal melanoma","volume":"14","author":"Eldh","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib106","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/COC.0000000000000033","article-title":"Yttrium-90 microsphere brachytherapy for liver metastases from uveal melanoma: clinical outcomes and the predictive value of fluorodeoxyglucose positron emission tomography","volume":"39","author":"Eldredge-Hindy","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib107","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1504\/IJBET.2012.045355","article-title":"Enhancing survival prognostication in patients with choroidal melanoma by integrating pathologic, clinical and genetic predictors of metastasis","volume":"8","author":"Eleuteri","year":"2012","journal-title":"Int. J. Biomed. Eng. Technol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib108","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.compbiomed.2018.09.024","article-title":"Prognostication of metastatic death in uveal melanoma patients: a Markov multi-state model","volume":"102","author":"Eleuteri","year":"2018","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.preteyeres.2022.101041_bib109","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S0161-6420(00)00608-4","article-title":"Reply to: uveal melanoma: implications of tumor doubling time","volume":"108","author":"Eskelin","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib110","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/archopht.120.5.676","article-title":"Imaging to detect metastases from malignant uveal melanoma","volume":"120","author":"Eskelin","year":"2002","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib111","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/cncr.11113","article-title":"A prognostic model and staging for metastatic uveal melanoma","volume":"97","author":"Eskelin","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib112","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S0161-6420(00)00182-2","article-title":"Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment","volume":"107","author":"Eskelin","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib113","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1151::AID-CNCR20>3.0.CO;2-G","article-title":"Screening for metastatic malignant melanoma of the uvea revisited","volume":"85","author":"Eskelin","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib115","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000488708","article-title":"Metastatic cutaneous melanoma presenting with choroidal metastasis simulating primary uveal melanoma","volume":"5","author":"Everett","year":"2019","journal-title":"Ocul. Oncol. Pathol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib116","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1470-2045(12)70269-3","article-title":"Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial","volume":"13","author":"Falchook","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib117","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1179\/joc.2011.23.5.300","article-title":"Liver metastases from melanoma: hepatic intra-arterial chemotherapy. A retrospective study","volume":"23","author":"Farolfi","year":"2011","journal-title":"J. Chemother."},{"key":"10.1016\/j.preteyeres.2022.101041_bib118","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/archophthalmol.2009.401","article-title":"Hepatic abnormalities identified on abdominal computed tomography at diagnosis of uveal melanoma","volume":"128","author":"Feinstein","year":"2010","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib119","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1477-3163-6-6","article-title":"Immunohistochemical expression of melan-A and tyrosinase in uveal melanoma","volume":"6","author":"Fernandes","year":"2007","journal-title":"J. Carcinog."},{"key":"10.1016\/j.preteyeres.2022.101041_bib120","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1200\/JCO.2008.20.1558","article-title":"Palliative cancer care a decade later: accomplishments, the need, next steps -- from the American Society of Clinical Oncology","volume":"27","author":"Ferris","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib121","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1136\/bjo.2003.039289","article-title":"Whole body PET\/CT imaging for detection of metastatic choroidal melanoma","volume":"88","author":"Finger","year":"2004","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib122","first-page":"131","article-title":"Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study","volume":"23","author":"Fiorentini","year":"2009","journal-title":"In Vivo"},{"key":"10.1016\/j.preteyeres.2022.101041_bib123","doi-asserted-by":"crossref","first-page":"326S","DOI":"10.1038\/jid.1993.57","article-title":"Tumor progression in ocular melanomas","volume":"100","author":"Folberg","year":"1993","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib124","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/jso.23501","article-title":"Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience","volume":"109","author":"Forster","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib125","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/cancers11020152","article-title":"Adjuvant ipilimumab in high-risk uveal melanoma","volume":"11","author":"Fountain","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.preteyeres.2022.101041_bib126","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archopht.1984.01040030064036","article-title":"Resection of solitary metastasis. Approach to palliative treatment of hepatic involvement with choroidal melanoma","volume":"102","author":"Fournier","year":"1984","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib127","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1136\/bjophthalmol-2018-312612","article-title":"Hepatic abnormalities identified by staging MRI and accuracy of MRI of patients with uveal melanoma","volume":"103","author":"Francis","year":"2019","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib128","series-title":"American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Meeting","first-page":"382","article-title":"Surveillance options for patients with uveal melanoma following definitive management","author":"Francis","year":"2013"},{"key":"10.1016\/j.preteyeres.2022.101041_bib129","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.ejso.2006.04.011","article-title":"Detection of metastatic disease in patients with uveal melanoma using positron emission tomography","volume":"32","author":"Francken","year":"2006","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib130","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/bjo.2008.153684","article-title":"Long-term survival of uveal melanoma patients after surgery for liver metastases","volume":"93","author":"Frenkel","year":"2009","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib131","doi-asserted-by":"crossref","first-page":"236","DOI":"10.5301\/ejo.5000049","article-title":"Initial PET\/CT staging for choroidal melanoma: AJCC correlation and second nonocular primaries in 333 patients","volume":"22","author":"Freton","year":"2012","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib132","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0039-6257(04)00115-8","article-title":"Whole-body fluorine-18 fluordeoxyglucose positron emission tomography\/computed tomography (FDG-PET\/CT) in staging of advanced uveal melanoma","volume":"49","author":"Freudenberg","year":"2004","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib133","first-page":"169","article-title":"An immunohistochemical and prognostic analysis of cytokeratin expression in malignant uveal melanoma","volume":"141","author":"Fuchs","year":"1992","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib134","article-title":"Patients presenting with metastases: stage IV uveal melanoma, an international study","author":"Garg","year":"2021","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib135","series-title":"AJCC Cancer Staging Manual","first-page":"563","article-title":"Melanoma of the skin","author":"Gershenwald","year":"2017"},{"key":"10.1016\/j.preteyeres.2022.101041_bib136","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.ophtha.2004.06.022","article-title":"Geographic disparities in diagnostic screening for metastatic uveal melanoma","volume":"111","author":"Gombos","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib137","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/jso.23535","article-title":"The Liverpool uveal melanoma liver metastases pathway: outcome following liver resection","volume":"109","author":"Gomez","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib138","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1148\/radiol.2019190199","article-title":"A prospective phase II trial of radioembolization for treatment of uveal melanoma hepatic metastasis","volume":"293","author":"Gonsalves","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib139","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2214\/AJR.14.14001","article-title":"Uveal melanoma metastatic to the liver: chemoembolization with 1,3-bis-(2-chloroethyl)-1-nitrosourea","volume":"205","author":"Gonsalves","year":"2015","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib140","series-title":"Handbook of Statistics in Clinical Oncology","first-page":"513","article-title":"Why Kaplan\u2013Meier fails and cumulative incidence succeeds when estimating failure probabilities in the presence of competing risks","author":"Gooley","year":"2001"},{"key":"10.1016\/j.preteyeres.2022.101041_bib141","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0161-6420(91)32285-1","article-title":"Survival of patients with metastases from uveal melanoma","volume":"98","author":"Gragoudas","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib142","first-page":"180","article-title":"The staging of cancer: a retrospective and prospective appraisal","volume":"58","author":"Greene","year":"2008","journal-title":"Ca - Cancer J. Clin."},{"key":"10.1016\/j.preteyeres.2022.101041_bib143","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2016.01.010","article-title":"Oncogene status as a diagnostic tool in ocular and cutaneous melanoma","volume":"57","author":"Griewank","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib144","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/modpathol.2013.138","article-title":"Genetic and clinico-pathologic analysis of metastatic uveal melanoma","volume":"27","author":"Griewank","year":"2014","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib145","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-13-0163","article-title":"Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas","volume":"19","author":"Griewank","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib146","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9535","article-title":"Clinical characteristics of SF3B1 mutant (mut) uveal melanoma (UM) and response to immune checkpoint inhibition (ICI)","volume":"39","author":"Grimes","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib147","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jamaophthalmol.2013.2547","article-title":"Progression of ocular melanoma metastasis to the liver: the 2012 Zimmerman lecture","volume":"131","author":"Grossniklaus","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2022.101041_bib148","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ophtha.2018.09.031","article-title":"Understanding uveal melanoma metastasis to the liver: the Zimmerman effect and the Zimmerman hypothesis","volume":"126","author":"Grossniklaus","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib149","series-title":"WHO Classification of Tumours of the Eye","first-page":"87","article-title":"Tumours of the choroid","author":"Grossniklaus","year":"2018"},{"key":"10.1016\/j.preteyeres.2022.101041_bib150","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.humpath.2016.07.012","article-title":"Metastatic ocular melanoma to the liver exhibits infiltrative and nodular growth patterns","volume":"57","author":"Grossniklaus","year":"2016","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib151","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0002-9394(99)80162-7","article-title":"Surgical removal of solitary hepatic metastasis from choroidal melanoma","volume":"125","author":"Gunduz","year":"1998","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib152","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/COC.0b013e3181b4b065","article-title":"Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: response, survival, and prognostic factors","volume":"33","author":"Gupta","year":"2010","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib153","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000442950","article-title":"Reduction of nodular growth pattern of metastatic uveal melanoma after radioembolization of hepatic metastases","volume":"2","author":"Halenda","year":"2016","journal-title":"Ocul. Oncol. Pathol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib154","first-page":"347","article-title":"Keratin 20 - a diagnostic and prognostic marker in colorectal cancer? Histol","volume":"27","author":"Harbaum","year":"2012","journal-title":"Histopathol"},{"key":"10.1016\/j.preteyeres.2022.101041_bib155","article-title":"The DecisionDx-UM gene expression profile test provides risk stratification and individualized patient care in uveal melanoma","volume":"5","author":"Harbour","year":"2013","journal-title":"PLoS currents"},{"key":"10.1016\/j.preteyeres.2022.101041_bib156","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/ng.2523","article-title":"Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma","volume":"45","author":"Harbour","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.preteyeres.2022.101041_bib157","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000206139","article-title":"Osteopontin and \u2018melanoma inhibitory activity\u2019: comparison of two serological tumor markers in metastatic uveal melanoma patients","volume":"223","author":"Haritoglou","year":"2009","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.preteyeres.2022.101041_bib158","series-title":"Paper Presented at the AACR Annual Meeting 2021, Virtual, Paper No. 1673","article-title":"Uveal melanoma study patients with low CD163:CD3 ratio in tumor biopsy and low serum IL-6 showed enhanced tumor shrinkage (TS) and overall survival (OS) on tebentafusp","author":"Hassel","year":"2021"},{"key":"10.1016\/j.preteyeres.2022.101041_bib159","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/00008390-200008000-00006","article-title":"Immunohistochemical diagnosis of malignant melanoma of the conjunctiva and uvea: comparison of the novel antibody against melan-A with S100 protein and HMB-45","volume":"10","author":"Heegaard","year":"2000","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib160","first-page":"153","article-title":"Biologic determinants of uveal melanoma metastatic phenotype: role of intermediate filaments as predictive markers","volume":"78","author":"Hendrix","year":"1998","journal-title":"Lab. Invest."},{"key":"10.1016\/j.preteyeres.2022.101041_bib161","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s40425-019-0800-0","article-title":"Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study","volume":"7","author":"Heppt","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib162","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2017.05.038","article-title":"Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1\/cytotoxic T-lymphocyte antigen-4 inhibition","volume":"82","author":"Heppt","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib163","first-page":"1151","article-title":"Transarterial hepatic chemoperfusion of uveal melanoma metastases: survival and response to treatment","volume":"183","author":"Heusner","year":"2011","journal-title":"R\u00f6fo"},{"key":"10.1016\/j.preteyeres.2022.101041_bib164","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/eye.1998.245","article-title":"Predictive power of screening tests for metastasis in uveal melanoma","volume":"12","author":"Hicks","year":"1998","journal-title":"Eye"},{"key":"10.1016\/j.preteyeres.2022.101041_bib165","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001501","article-title":"Comprehensive analysis of cutaneous and uveal melanoma liver metastases","volume":"8","author":"Hoefsmit","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib166","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1078-0432.CCR-08-2243","article-title":"Overexpression of the KIT\/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate","volume":"15","author":"Hofmann","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib167","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/CMR.0b013e3283403ce9","article-title":"Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma","volume":"20","author":"Homsi","year":"2010","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib168","first-page":"407","article-title":"[Studies on the presence of free cells of malignant melanoma of the uvea in peripheral blood]","volume":"39","author":"Horode\u0144ski","year":"1969","journal-title":"Klin. Oczna."},{"key":"10.1016\/j.preteyeres.2022.101041_bib169","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/cncr.11872","article-title":"Prolonged survival after complete resection of metastases from intraocular melanoma","volume":"100","author":"Hsueh","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib170","first-page":"659","volume":"vol. 21","author":"Hui","year":"2013"},{"key":"10.1016\/j.preteyeres.2022.101041_bib171","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/j.ejrad.2009.03.064","article-title":"Transarterial chemoembolization of liver metastases in patients with uveal melanoma","volume":"74","author":"Huppert","year":"2010","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib172","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/CMR.0000000000000343","article-title":"A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy","volume":"27","author":"Itchins","year":"2017","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib173","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.preteyeres.2022.101041_bib174","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3390\/cancers11071007","article-title":"Metastatic uveal melanoma: treatment strategies and survival-results from the Dutch melanoma treatment registry","volume":"11","author":"Jochems","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.preteyeres.2022.101041_bib175","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.18632\/oncotarget.6614","article-title":"Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4","volume":"7","author":"Johansson","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.preteyeres.2022.101041_bib176","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1038\/s41467-020-16276-8","article-title":"Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours","volume":"11","author":"Johansson","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.preteyeres.2022.101041_bib177","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00251-019-01108-x","article-title":"Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab","volume":"71","author":"Johansson","year":"2019","journal-title":"Immunogenetics"},{"key":"10.1016\/j.preteyeres.2022.101041_bib178","doi-asserted-by":"crossref","first-page":"114","DOI":"10.6004\/jnccn.2018.7070","article-title":"Response to anti-PD-1 in uveal melanoma without high-volume liver metastasis","volume":"17","author":"Johnson","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.preteyeres.2022.101041_bib179","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s12885-019-5712-3","article-title":"Natural killer cells and pigment epithelial-derived factor control the infiltrative and nodular growth of hepatic metastases in an Orthotopic murine model of ocular melanoma","volume":"19","author":"Jones","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib180","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9509","article-title":"Overall survival benefit from tebentafusp in patients with best response of progressive disease","volume":"39","author":"Joshua","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib181","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/CMR.0000000000000175","article-title":"A phase 2 study of tremelimumab in patients with advanced uveal melanoma","volume":"25","author":"Joshua","year":"2015","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib415","article-title":"Presumed incipient choroidal melanoma: proposed diagnostic criteria and management","author":"Jouhi","year":"2021","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib182","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ajo.2019.01.031","article-title":"The small fatal choroidal melanoma study. A survey by the European ophthalmic oncology group","volume":"202","author":"Jouhi","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib183","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1167\/iovs.05-0422","article-title":"Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study","volume":"47","author":"Kadkol","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2022.101041_bib184","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ajo.2003.08.045","article-title":"Liver function tests in metastatic uveal melanoma","volume":"137","author":"Kaiserman","year":"2004","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib185","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1038\/s41388-021-01919-x","article-title":"Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth","volume":"40","author":"Kaluz","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.preteyeres.2022.101041_bib186","first-page":"3560640","article-title":"Nivolumab and ipilimumab in the treatment of metastatic uveal melanoma: a single-center experience","volume":"17","author":"Karivedu","year":"2019","journal-title":"Case Rep. Oncol. Med."},{"key":"10.1016\/j.preteyeres.2022.101041_bib187","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1143997","article-title":"Clinical activity and safety of pembrolizumab in ipilimumab pre-treated patients with uveal melanoma","volume":"5","author":"Karydis","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib188","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/jso.24956","article-title":"Percutaneous hepatic perfusion with melphalan in uveal melanoma: a safe and effective treatment modality in an orphan disease","volume":"117","author":"Karydis","year":"2018","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib189","doi-asserted-by":"crossref","first-page":"S314","DOI":"10.1016\/j.jacr.2017.01.037","article-title":"ACR appropriateness Criteria\u00ae suspected liver metastases","volume":"14","author":"Kaur","year":"2017","journal-title":"J. Am. Coll. Radiol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib190","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40425-018-0459-y","article-title":"Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial","volume":"7","author":"Keilholz","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib191","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3109\/0284186X.2013.786839","article-title":"Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working Group on Immunotherapy of Oncology (WIN-O)","volume":"52","author":"Kelderman","year":"2013","journal-title":"Acta Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib192","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an International Rare Cancers Initiative (IRCI) ocular melanoma study","volume":"30","author":"Khoja","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib193","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/archophthalmol.2010.121","article-title":"Survival in patients with presymptomatic diagnosis of metastatic uveal melanoma","volume":"128","author":"Kim","year":"2010","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib194","doi-asserted-by":"crossref","first-page":"28903","DOI":"10.18632\/oncotarget.25627","article-title":"Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients","volume":"9","author":"Kirchberger","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.preteyeres.2022.101041_bib195","series-title":"Ocular Melanoma: Advances in Diagnostic and Therapeutic Strategies","first-page":"20","article-title":"Incidence, prevalence and epidemiology of ocular melanoma","author":"Kivel\u00e4","year":"2014"},{"key":"10.1016\/j.preteyeres.2022.101041_bib196","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/01.iio.0000195861.71558.13","article-title":"Metastatic uveal melanoma","volume":"46","author":"Kivel\u00e4","year":"2006","journal-title":"Int. Ophthalmol. Clin."},{"key":"10.1016\/j.preteyeres.2022.101041_bib197","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0959-8049(03)00132-1","article-title":"Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma","volume":"39","author":"Kivel\u00e4","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib198","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ajo.2016.06.002","article-title":"Validation of a prognostic staging for metastatic uveal melanoma: a collaborative study of the European Ophthalmic Oncology Group","volume":"168","author":"Kivel\u00e4","year":"2016","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib199","article-title":"Dataset for \"Validation of a prognostic staging for metastatic uveal melanoma: a collaborative study of the European Ophthalmic Oncology Group","author":"Kivel\u00e4","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib200","series-title":"AJCC Cancer Staging Manual","first-page":"813","article-title":"Uveal melanoma","author":"Kivel\u00e4","year":"2017"},{"key":"10.1016\/j.preteyeres.2022.101041_bib201","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000341","article-title":"Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma","volume":"8","author":"Klemen","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib202","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/CMR.0b013e328347105e","article-title":"Receiver operating characteristic analysis: calculation for the marker 'melanoma inhibitory activity' in metastatic uveal melanoma patients","volume":"21","author":"Klingenstein","year":"2011","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib203","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/CMR.0b013e3283403d6c","article-title":"Whole-body F-18-fluoro-2-deoxyglucose positron emission tomography\/computed tomography imaging in the follow-up of metastatic uveal melanoma","volume":"20","author":"Klingenstein","year":"2010","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib204","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s00270-012-0373-5","article-title":"Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients","volume":"36","author":"Klingenstein","year":"2013","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib205","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s00417-005-1188-8","article-title":"Prognostic factors of liver metastases from uveal melanoma","volume":"243","author":"Kodjikian","year":"2005","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib206","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s00417-004-1057-x","article-title":"Prolonged survival after resection of liver metastases from uveal melanoma and intra-arterial chemotherapy","volume":"243","author":"Kodjikian","year":"2005","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib207","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13000-018-0751-7","article-title":"Expression of HMB45, MelanA and SOX10 is rare in non-small cell lung cancer","volume":"13","author":"Kriegsmann","year":"2018","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib208","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.2012.45.2771","article-title":"Staging of ciliary body and choroidal melanomas based on anatomic extent","volume":"31","author":"Kujala","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib209","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1167\/iovs.03-0538","article-title":"Very long-term prognosis of patients with malignant uveal melanoma","volume":"44","author":"Kujala","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2022.101041_bib210","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ajo.2005.02.051","article-title":"Whole body positron emission tomography\/computed tomography staging of metastatic choroidal melanoma","volume":"140","author":"Kurli","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib211","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00428-007-0555-8","article-title":"Occurrence of ocular melanoma thirteen years after skin melanoma: two separate primaries or metastatic disease? A case solved with NRAS and CDKN2A (INK4A-ARF) mutational analysis","volume":"452","author":"K\u00fcsters-Vandevelde","year":"2008","journal-title":"Virchows Arch."},{"key":"10.1016\/j.preteyeres.2022.101041_bib212","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/j.ophtha.2009.04.044","article-title":"Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis","volume":"116","author":"Lane","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib213","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/jamaophthalmol.2018.2466","article-title":"Survival rates in patients after treatment for metastasis from uveal melanoma","volume":"136","author":"Lane","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2022.101041_bib214","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s10585-013-9596-3","article-title":"Host pigment epithelium-derived factor (PEDF) prevents progression of liver metastasis in a mouse model of uveal melanoma","volume":"30","author":"Lattier","year":"2013","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.preteyeres.2022.101041_bib215","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1136\/jclinpath-2012-201109","article-title":"Use of immunohistochemistry in the diagnosis of problematic breast lesions","volume":"66","author":"Lee","year":"2013","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib216","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1093\/annonc\/mdv207","article-title":"Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancer","volume":"26","author":"Lee","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib217","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.4143\/crt.2017.535","article-title":"Genetic alterations among Korean melanoma patients showing tumor heterogeneity: a comparison between primary tumors and corresponding metastatic lesions","volume":"50","author":"Lee","year":"2018","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.preteyeres.2022.101041_bib218","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.lungcan.2013.06.023","article-title":"What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?--Results from the lung cancer economics and outcomes research (LUCEOR) study","volume":"82","author":"Lester","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib219","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00270-019-02366-8","article-title":"Predictors of overall and progression-free survival in patients with ocular melanoma metastatic to the liver undergoing Y90 radioembolization","volume":"43","author":"Levey","year":"2020","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib220","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/annonc\/mdt585","article-title":"Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial","volume":"25","author":"Leyvraz","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib221","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1200\/JCO.1997.15.7.2589","article-title":"Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy","volume":"15","author":"Leyvraz","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib222","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1167\/iovs.07-1035","article-title":"Differential expression of chemokine receptors on uveal melanoma cells and their metastases","volume":"49","author":"Li","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2022.101041_bib223","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ophtha.2017.09.029","article-title":"Radiologic and histopathologic correlation of different growth patterns of metastatic uveal melanoma to the liver","volume":"125","author":"Liao","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib224","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","article-title":"Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials","volume":"17","author":"Long","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib225","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.4143\/crt.2017.171","article-title":"Prognostic factors and decision tree for long-term survival in metastatic uveal melanoma","volume":"50","author":"Lorenzo","year":"2018","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.preteyeres.2022.101041_bib226","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10384-019-00656-9","article-title":"Clinical predictors of survival in metastatic uveal melanoma","volume":"63","author":"Lorenzo","year":"2019","journal-title":"Jpn. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib227","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1002\/cncr.28282","article-title":"Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the dana-farber cancer Institute, Massachusetts general hospital, memorial sloan-kettering cancer center, and university hospital of lausanne experience","volume":"119","author":"Luke","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib228","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1078-0432.CCR-19-1223","article-title":"Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201)","volume":"26","author":"Luke","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib229","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/bjophthalmol-2014-305371","article-title":"Uveal melanoma hepatic metastases mutation spectrum analysis using targeted next-generation sequencing of 400 cancer genes","volume":"99","author":"Luscan","year":"2015","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib230","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/(SICI)1097-0142(19961101)78:9<1967::AID-CNCR18>3.0.CO;2-W","article-title":"Metastatic uveal melanoma. A morphologic and immunohistochemical analysis","volume":"78","author":"Luyten","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib231","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181970","article-title":"Overtreatment in the United States","volume":"12","author":"Lyu","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.preteyeres.2022.101041_bib232","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1158\/1078-0432.CCR-12-0309","article-title":"Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma","volume":"18","author":"Madic","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib233","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/jjco\/hym018","article-title":"Magnetic resonance screening trial for hepatic metastasis in patients with locally controlled choroidal melanoma","volume":"37","author":"Maeda","year":"2007","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib234","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/CMR.0b013e328358b373","article-title":"A pilot study of sunitinib malate in patients with metastatic uveal melanoma","volume":"22","author":"Mahipal","year":"2012","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib235","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1093\/annonc\/mdt376","article-title":"Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma","volume":"24","author":"Maio","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib236","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1111\/aos.12523","article-title":"Small metastasizing choroidal melanomas","volume":"93","author":"Malcl\u00e8s","year":"2015","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib237","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ejso.2016.02.019","article-title":"Radiofrequency ablation and surgical resection of liver metastases from uveal melanoma","volume":"42","author":"Mariani","year":"2016","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib238","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3390\/cancers11060863","article-title":"Development of a prognostic nomogram for liver metastasis of uveal melanoma patients selected by liver MRI","volume":"11","author":"Mariani","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.preteyeres.2022.101041_bib239","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.ejso.2009.02.016","article-title":"Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie","volume":"35","author":"Mariani","year":"2009","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib240","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/bjophthalmol-2012-302323","article-title":"MRI in the detection of hepatic metastases from high-risk uveal melanoma: a prospective study in 188 patients","volume":"97","author":"Marshall","year":"2013","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib241","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ng.2674","article-title":"Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3","volume":"45","author":"Martin","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.preteyeres.2022.101041_bib242","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.bulcan.2018.07.011","article-title":"Prise en charge des m\u00e9lanomes oculaires, le minimum pour les oncologues","volume":"105","author":"Mathis","year":"2018","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib243","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jama.1988.03410070102037","article-title":"Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge","volume":"260","author":"Mavligit","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.preteyeres.2022.101041_bib244","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1007\/s00330-012-2499-x","article-title":"Assessment of pulmonary melanoma metastases with 18F-FDG PET\/CT: which PET-negative patients require additional tests for definitive staging?","volume":"22","author":"Mayerhoefer","year":"2012","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib245","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1001\/jamaophthalmol.2019.5710","article-title":"Accuracy of the Cancer Genome Atlas classification vs American Joint Committee on Cancer classification for prediction of metastasis in patients with uveal melanoma","volume":"138","author":"Mazloumi","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2022.101041_bib246","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/pcmr.12433","article-title":"Insights into genetic alterations of liver metastases from uveal melanoma","volume":"29","author":"McCarthy","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.preteyeres.2022.101041_bib247","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0002-9394(14)77876-6","article-title":"A randomized study of methanol-extraction residue of bacille Calmette-Guerin as postsurgical adjuvant therapy of uveal melanoma","volume":"110","author":"McLean","year":"1990","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib248","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1001\/archopht.1980.01020040150028","article-title":"Choroidal melanoma","volume":"98","author":"McLean","year":"1980","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib249","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0046-8177(82)80116-0","article-title":"Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis","volume":"13","author":"McLean","year":"1982","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib250","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0002-9394(14)77914-0","article-title":"Modifications of callender's classification of uveal melanoma at the armed forces Institute of pathology","volume":"96","author":"McLean","year":"1983","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib251","first-page":"1157","article-title":"Liver metastases from uveal melanoma: clinical experience of hepatic arterial infusion of cisplatin, vinblastine and dacarbazine","volume":"56","author":"Melichar","year":"2009","journal-title":"Hepato-Gastroenterology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib252","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","article-title":"Tebentafusp, a TCR\/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma","volume":"26","author":"Middleton","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib253","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000099151","article-title":"S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests","volume":"28","author":"Missotten","year":"2007","journal-title":"Tumour Biol"},{"key":"10.1016\/j.preteyeres.2022.101041_bib254","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1001\/archopht.121.8.1117","article-title":"Prognostic value of S-100-beta serum concentration in patients with uveal melanoma","volume":"121","author":"Missotten","year":"2003","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib255","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/ng.3549","article-title":"Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma","volume":"48","author":"Moore","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.preteyeres.2022.101041_bib256","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.ophtha.2012.01.045","article-title":"Liver function testing is not helpful for early diagnosis of metastatic uveal melanoma","volume":"119","author":"Mouriaux","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib257","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/bjc.2016.119","article-title":"Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study","volume":"115","author":"Mouriaux","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib258","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000331","article-title":"Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study","volume":"8","author":"Najjar","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib259","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/CMR.0000000000000617","article-title":"Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: a single-institution retrospective study","volume":"30","author":"Namikawa","year":"2020","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib260","first-page":"201","article-title":"BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy","volume":"16","author":"Nathan","year":"1997","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib261","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/j.ejca.2015.07.013","article-title":"Uveal melanoma UK national guidelines","volume":"51","author":"Nathan","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib262","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2022.101041_bib263","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.preteyeres.2022.101041_bib264","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12885-021-07865-x","article-title":"Involvement of mutant and wild-type CYSLTR2 in the development and progression of uveal nevi and melanoma","volume":"21","author":"Nell","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib265","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/CMR.0000000000000468","article-title":"Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: the Princess Margaret Cancer Centre experience","volume":"28","author":"Nicholas","year":"2018","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib266","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IIO.0000000000000160","article-title":"Micrometastatic dormancy in uveal melanoma: a comprehensive review of the evidence, mechanisms, and implications for future adjuvant therapies","volume":"57","author":"Nichols","year":"2017","journal-title":"Int. Ophthalmol. Clin."},{"key":"10.1016\/j.preteyeres.2022.101041_bib267","doi-asserted-by":"crossref","first-page":"e696","DOI":"10.1111\/aos.12432","article-title":"Response of patients with metastatic uveal melanoma to combined treatment with fotemustine and sorafenib","volume":"92","author":"Niederkorn","year":"2014","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib268","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.preteyeres.2009.06.002","article-title":"Immune escape mechanisms of intraocular tumors","volume":"28","author":"Niederkorn","year":"2009","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib269","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/bjc.2015.192","article-title":"Best supportive care in clinical trials: review of the inconsistency in control arm design","volume":"113","author":"Nipp","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib270","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1158\/0008-5472.CAN-15-2468","article-title":"Melanoma cells block PEDF production in fibroblasts to induce the tumor-promoting phenotype of cancer-associated fibroblasts","volume":"76","author":"Nwani","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib271","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1067\/mjd.2001.117526","article-title":"Microphthalmia transcription factor immunohistochemistry: a useful diagnostic marker in the diagnosis and detection of cutaneous melanoma, sentinel lymph node metastases, and extracutaneous melanocytic neoplasms","volume":"45","author":"O'Reilly","year":"2001","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib273","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.ophtha.2012.02.017","article-title":"Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma","volume":"119","author":"Onken","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib274","doi-asserted-by":"crossref","first-page":"7205","DOI":"10.1158\/0008-5472.CAN-04-1750","article-title":"Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death","volume":"64","author":"Onken","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib275","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/CMR.0b013e32834d3dcb","article-title":"(18 F-fluorodeoxyglucose positron emission tomography\/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study","volume":"22","author":"Orcurto","year":"2012","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib276","first-page":"98","article-title":"The distribution of secondary growths in cancer of the breast. 1889","volume":"8","author":"Paget","year":"1989","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.preteyeres.2022.101041_bib277","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1167\/iovs.15-16532","article-title":"Nationwide incidence of ocular melanoma in South Korea by using the national cancer registry database (1999-2011)","volume":"56","author":"Park","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2022.101041_bib278","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1755-3768.2008.01327.x","article-title":"Long-term outcome of transpupillary thermotherapy as primary treatment of selected choroidal melanoma","volume":"87","author":"Parrozzani","year":"2009","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib279","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00008390-200508000-00011","article-title":"Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study","volume":"15","author":"Patel","year":"2005","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib280","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1001\/archophthalmol.2011.263","article-title":"Characterization of computed tomography scan abnormalities in patients with biopsy-proven hepatic metastases from uveal melanoma","volume":"129","author":"Patel","year":"2011","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib281","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1136\/bjo.85.10.1208","article-title":"Cell proliferation activity in posterior uveal melanoma after Ru-106 brachytherapy: an EORTC ocular oncology group study","volume":"85","author":"Pe'er","year":"2001","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib282","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.20.00605","article-title":"Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study","volume":"39","author":"Pelster","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib283","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10637-008-9143-2","article-title":"O-Mel-Inib: a Canc\u00e9ro-p\u00f4le Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma","volume":"26","author":"Penel","year":"2008","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.preteyeres.2022.101041_bib284","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/annonc\/mdl009","article-title":"Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients","volume":"17","author":"Peters","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib285","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00001813-200306000-00002","article-title":"Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study","volume":"14","author":"Pf\u00f6hler","year":"2003","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.preteyeres.2022.101041_bib286","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1634\/theoncologist.2015-0501","article-title":"Phase II trial of bevacizumab in combination with temozolomide as first-line treatment in patients with metastatic uveal melanoma","volume":"21","author":"Piperno-Neumann","year":"2016","journal-title":"Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib287","series-title":"Paper Presented at the AACR Annual Meeting 2021, Virtual, Paper No. 5342","article-title":"Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma","author":"Piperno-Neumann","year":"2021"},{"key":"10.1016\/j.preteyeres.2022.101041_bib288","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1158\/1535-7163.MCT-19-0098","article-title":"Genomic profiling of metastatic uveal melanoma and clinical results of a phase I study of the protein kinase C inhibitor AEB071","volume":"19","author":"Piperno-Neumann","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.preteyeres.2022.101041_bib289","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3390\/cancers11060817","article-title":"Uveal melanoma: a European network to face the many challenges of a rare cancer","volume":"11","author":"Piperno-Neumann","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.preteyeres.2022.101041_bib290","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9502","article-title":"A randomized multicenter phase 3 trial of adjuvant fotemustine versus surveillance in high risk uveal melanoma (UM) patients (FOTEADJ)","volume":"35","author":"Piperno-Neumann","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib291","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jfo.2015.04.005","article-title":"Prospective study of surveillance testing for metastasis in 100 high-risk uveal melanoma patients","volume":"38","author":"Piperno-Neumann","year":"2015","journal-title":"J. Fr. Ophtalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib292","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.20.00550","article-title":"Nivolumab plus ipilimumab for treatment-na\u00efve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)","volume":"39","author":"Piulats","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib293","first-page":"5325762","article-title":"Clinical performance and management outcomes with the DecisionDx-UM gene expression profile test in a prospective multicenter study","volume":"2016","author":"Plasseraud","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib294","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/CMR.0b013e3283457726","article-title":"Metastatic uveal melanoma: is there a role for conventional chemotherapy? A single center study based on 58 patients","volume":"21","author":"Pons","year":"2011","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib295","doi-asserted-by":"crossref","first-page":"350","DOI":"10.2967\/jnumed.119.230870","article-title":"First-line selective internal radiation therapy in patients with uveal melanoma metastatic to the liver","volume":"61","author":"Ponti","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.preteyeres.2022.101041_bib296","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/cncr.10996","article-title":"Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma","volume":"95","author":"Pyrh\u00f6nen","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib297","first-page":"1","article-title":"Uveal melanoma in Finland. An epidemiological, clinical, histological and prognostic study","volume":"55","author":"Raivio","year":"1977","journal-title":"Acta Ophthalmol. Suppl."},{"key":"10.1016\/j.preteyeres.2022.101041_bib298","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/1097-0142(19830715)52:2<334::AID-CNCR2820520225>3.0.CO;2-E","article-title":"Survival in metastatic ocular melanoma","volume":"52","author":"Rajpal","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib299","article-title":"Dataset for \"Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis","author":"Rantala","year":"2018","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib300","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","article-title":"Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis","volume":"29","author":"Rantala","year":"2019","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib301","article-title":"Dataset for \"Metastatic uveal melanoma managed with best supportive care","author":"Rantala","year":"2020","journal-title":"Acta Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib302","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/0284186X.2020.1817978","article-title":"Metastatic uveal melanoma managed with best supportive care","volume":"60","author":"Rantala","year":"2021","journal-title":"Acta Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib303","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/CMR.0000000000000728","article-title":"Impact of staging on survival outcomes: a nationwide real-world cohort study of metastatic uveal melanoma","volume":"31","author":"Rantala","year":"2021","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib304","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ajo.2020.03.049","article-title":"Hepatic ultrasonography compared with computed tomography and magnetic resonance imaging at diagnosis of metastatic uveal melanoma","volume":"216","author":"Rantala","year":"2020","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib305","first-page":"120","article-title":"NCCN guidelines insights: uveal melanoma, version 1.2019","volume":"18","author":"Rao","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.preteyeres.2022.101041_bib306","doi-asserted-by":"crossref","first-page":"TPS9604","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS9604","article-title":"Phase II single-arm multicenter study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma","volume":"37","author":"Rapisuwon","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib307","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00417-005-1171-4","article-title":"Melanoma inhibitory activity\" (MIA): a promising serological tumour marker in metastatic uveal melanoma","volume":"243","author":"Reiniger","year":"2005","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib308","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/pcmr.12892","article-title":"Germline loss-of-function variants in MBD4 are rare in Finnish patients with uveal melanoma","volume":"33","author":"Repo","year":"2020","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.preteyeres.2022.101041_bib309","doi-asserted-by":"crossref","first-page":"8076","DOI":"10.1200\/JCO.2005.02.6534","article-title":"Variates of survival in metastatic uveal melanoma","volume":"23","author":"Rietschel","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib310","first-page":"5712","article-title":"Lack of BRAF mutations in uveal melanoma","volume":"63","author":"Rimoldi","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib311","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1245\/ASO.2005.06.032","article-title":"Treatment of liver metastases from uveal melanoma","volume":"12","author":"Rivoire","year":"2005","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib312","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ccell.2017.12.013","article-title":"Integrative analysis identifies four molecular and clinical subsets in uveal melanoma","volume":"33","author":"Robertson","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.preteyeres.2022.101041_bib313","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archopht.126.8.1156","article-title":"Small choroidal melanomas treated with transpupillary thermotherapy and cryotherapy","volume":"126","author":"Robertson","year":"2008","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib314","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1158\/1078-0432.CCR-19-1215","article-title":"Evolutionary routes in metastatic uveal melanomas depend on MBD4 alterations","volume":"25","author":"Rodrigues","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib315","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1038\/s41467-018-04322-5","article-title":"Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors","volume":"9","author":"Rodrigues","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.preteyeres.2022.101041_bib316","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00262-019-02352-6","article-title":"Pembrolizumab as first-line treatment for metastatic uveal melanoma","volume":"68","author":"Rossi","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.preteyeres.2022.101041_bib317","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.ajhg.2016.09.008","article-title":"Comprehensive genetic landscape of uveal melanoma by whole-genome sequencing","volume":"99","author":"Royer-Bertrand","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.preteyeres.2022.101041_bib318","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/CMR.0000000000000653","article-title":"Phase Ib\/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)","volume":"30","author":"Rozeman","year":"2020","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib319","doi-asserted-by":"crossref","first-page":"S1441","DOI":"10.1016\/j.annonc.2020.10.552","article-title":"A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM)","volume":"31","author":"Sacco","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib320","doi-asserted-by":"crossref","first-page":"119478","DOI":"10.1016\/j.biomaterials.2019.119478","article-title":"Precision detection of liver metastasis by collagen-targeted protein MRI contrast agent","volume":"224","author":"Salarian","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.preteyeres.2022.101041_bib321","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0748-7983(98)91485-8","article-title":"Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy","volume":"24","author":"Salmon","year":"1998","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib322","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1200\/JCO.2008.16.0705","article-title":"Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor","volume":"26","author":"Sato","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib323","doi-asserted-by":"crossref","first-page":"9521","DOI":"10.1200\/JCO.2018.36.15_suppl.9521","article-title":"Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: overall survival findings","volume":"36","author":"Sato","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib324","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib325","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00008390-200212000-00009","article-title":"Melanoma inhibitory activity: a novel serum marker for uveal melanoma","volume":"12","author":"Schaller","year":"2002","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib326","doi-asserted-by":"crossref","first-page":"Mmt37","DOI":"10.2217\/mmt-2020-0001","article-title":"Prospective evaluation of risk-appropriate management of uveal melanoma patients informed by gene expression profiling","volume":"7","author":"Schefler","year":"2020","journal-title":"Melanoma Manag"},{"key":"10.1016\/j.preteyeres.2022.101041_bib327","article-title":"A single-center experience in radioembolization as salvage therapy of hepatic metastases of uveal melanoma","volume":"4","author":"Schelhorn","year":"2015","journal-title":"Acta Radiol. Open"},{"key":"10.1016\/j.preteyeres.2022.101041_bib328","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/CMR.0000000000000401","article-title":"Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study","volume":"27","author":"Schinzari","year":"2017","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib329","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00008390-200506000-00010","article-title":"Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma","volume":"15","author":"Schmittel","year":"2005","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib330","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/00008390-200510000-00014","article-title":"A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma","volume":"15","author":"Schmittel","year":"2005","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib331","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/CMR.0b013e328334c36e","article-title":"Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome","volume":"20","author":"Schuster","year":"2010","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib332","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/1097-0142(196111\/12)14:6<1272::AID-CNCR2820140618>3.0.CO;2-H","article-title":"A biomathematical approach to clinical tumor growth","volume":"14","author":"Schwartz","year":"1961","journal-title":"Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib333","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3390\/cancers12010117","article-title":"An outcome assessment of a single institution's longitudinal experience with uveal melanoma patients with liver metastasis","volume":"12","author":"Seedor","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.preteyeres.2022.101041_bib334","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.ejso.2019.06.036","article-title":"Iterative treatment with surgery and radiofrequency ablation of uveal melanoma liver metastasis: retrospective analysis of a series of very long-term survivors","volume":"45","author":"Servois","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib335","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejso.2009.08.010","article-title":"Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET)","volume":"36","author":"Servois","year":"2010","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib336","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1200\/JCO.20.00198","article-title":"Systemic therapy for melanoma: ASCO guideline","volume":"38","author":"Seth","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib337","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/CMR.0000000000000509","article-title":"Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma","volume":"28","author":"Shah","year":"2018","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib338","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/s41588-019-0440-9","article-title":"The genetic evolution of metastatic uveal melanoma","volume":"51","author":"Shain","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.preteyeres.2022.101041_bib339","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejca.2016.06.019","article-title":"GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis","volume":"65","author":"Sheng","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib340","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10147-017-1095-0","article-title":"Efficacy and toxicity of transarterial chemoembolization therapy using cisplatin and gelatin sponge in patients with liver metastases from uveal melanoma in an Asian population","volume":"22","author":"Shibayama","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib341","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/archophthalmol.2009.208","article-title":"Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes","volume":"127","author":"Shields","year":"2009","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib342","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1016\/j.ophtha.2013.03.012","article-title":"American Joint Committee on Cancer classification of posterior uveal melanoma (tumor size category) predicts prognosis in 7,731 patients","volume":"120","author":"Shields","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib343","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.ophtha.2015.01.026","article-title":"American Joint Committee on Cancer classification of uveal melanoma (anatomic stage) predicts prognosis in 7,731 patients: the 2013 Zimmerman Lecture","volume":"122","author":"Shields","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib344","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/IAE.0b013e31824d09a8","article-title":"Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases","volume":"32","author":"Shields","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2022.101041_bib345","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/archopht.118.9.1219","article-title":"Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients","volume":"118","author":"Shields","year":"2000","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib346","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0161-6420(01)00902-2","article-title":"Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: outcomes and limitations","volume":"109","author":"Shields","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib347","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/CMR.0000000000000234","article-title":"A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma","volume":"26","author":"Shoushtari","year":"2016","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib348","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ejso.2006.11.019","article-title":"Hepatic arterial fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma","volume":"33","author":"Siegel","year":"2007","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib349","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/bjo.2003.029058","article-title":"The Zimmerman-McLean-Foster hypothesis: 25 years later","volume":"88","author":"Singh","year":"2004","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib350","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0161-6420(03)00078-2","article-title":"Incidence of uveal melanoma in the United States: 1973-1997","volume":"110","author":"Singh","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib351","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.5858\/133.8.1223","article-title":"Chromosomal 3 and 8 status within hepatic metastasis of uveal melanoma","volume":"133","author":"Singh","year":"2009","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.preteyeres.2022.101041_bib352","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib353","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/jamaophthalmol.2020.5720","article-title":"Estimating cured fractions of uveal melanoma","volume":"139","author":"Singh","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2022.101041_bib354","doi-asserted-by":"crossref","first-page":"e1474","DOI":"10.1111\/aos.14847","article-title":"Posterior uveal melanoma incidence and survival by AJCC tumour size in a 70-year nationwide cohort","volume":"99","author":"Smidt-Nielsen","year":"2021","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib355","doi-asserted-by":"crossref","first-page":"100800","DOI":"10.1016\/j.preteyeres.2019.100800","article-title":"Uveal melanoma: towards a molecular understanding","volume":"75","author":"Smit","year":"2020","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib356","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.ophtha.2005.05.003","article-title":"Outcomes of iodine 125 plaque radiotherapy after initial observation of suspected small choroidal melanomas: a pilot study","volume":"112","author":"Sobrin","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib357","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/CMR.0b013e32823ed0d1","article-title":"A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment","volume":"17","author":"Solti","year":"2007","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib358","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12014-019-9230-8","article-title":"A multiplex immunoassay of serum biomarkers for the detection of uveal melanoma","volume":"16","author":"Song","year":"2019","journal-title":"Clin. Proteonomics"},{"key":"10.1016\/j.preteyeres.2022.101041_bib359","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s40259-016-0167-4","article-title":"Update on metastatic uveal melanoma: progress and challenges","volume":"30","author":"Spagnolo","year":"2016","journal-title":"BioDrugs"},{"key":"10.1016\/j.preteyeres.2022.101041_bib360","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/ijc.20690","article-title":"International uveal melanoma incidence trends in view of a decreasing proportion of morphological verification","volume":"114","author":"Stang","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.preteyeres.2022.101041_bib361","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1167\/tvst.8.6.12","article-title":"A panel of circulating microRNAs detects uveal melanoma with high precision","volume":"8","author":"Stark","year":"2019","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib362","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00432-020-03141-w","article-title":"Guidelines for uveal melanoma: a critical appraisal of systematically identified guidelines using the AGREE II and AGREE-REX instrument","volume":"146","author":"Steeb","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib363","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/diagnostics7010010","article-title":"Defining clinical response criteria and early response criteria for precision oncology: current state-of-the-art and future perspectives","volume":"7","author":"Subbiah","year":"2017","journal-title":"Diagnostics"},{"key":"10.1016\/j.preteyeres.2022.101041_bib364","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1755-3768.2009.01617.x","article-title":"Circulating melanoma cells in peripheral blood of patients with uveal melanoma before and after different therapies and association with prognostic parameters: a pilot study","volume":"89","author":"Suesskind","year":"2011","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib365","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/jamaophthalmol.2018.2986","article-title":"Association of uveal melanoma metastatic rate with stochastic mutation rate and type of mutation","volume":"136","author":"Szalai","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2022.101041_bib366","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav7504","article-title":"Chemokine receptor 4 targeted protein MRI contrast agent for early detection of liver metastases","volume":"6","author":"Tan","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.preteyeres.2022.101041_bib367","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non-small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2022.101041_bib368","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00432-004-0569-4","article-title":"Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma","volume":"130","author":"Terheyden","year":"2004","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib369","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s001050050823","article-title":"Immunochemotherapie des metastasierenden Uveamelanoms mit Interferon-alpha 2b, Interleukin-2 und Fotemustin","volume":"49","author":"Terheyden","year":"1998","journal-title":"Kasuistiken und Literatur\u00fcbersicht. Hautarzt"},{"key":"10.1016\/j.preteyeres.2022.101041_bib370","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/0197-2456(93)90052-F","article-title":"Design and methods of a clinical trial for a rare condition: the collaborative ocular melanoma study. COMS report No. 3. Control","volume":"14","year":"1993","journal-title":"Clin. Trials"},{"key":"10.1016\/j.preteyeres.2022.101041_bib371","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/archopht.119.5.670","article-title":"Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15","volume":"119","year":"2001","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib372","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer Institute of the United States, national cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.preteyeres.2022.101041_bib373","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/iovs.03-0622","article-title":"Microcirculation and tumor-infiltrating macrophages in choroidal and ciliary body melanoma and corresponding metastases","volume":"45","author":"Toivonen","year":"2004","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2022.101041_bib374","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1136\/bjo.2009.157933","article-title":"Time trends in the incidence of conjunctival melanoma in Sweden","volume":"93","author":"Triay","year":"2009","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib375","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1167\/iovs.08-2296","article-title":"Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases","volume":"50","author":"Trolet","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2022.101041_bib376","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1080\/0284186X.2018.1465587","article-title":"Selective internal radiation therapy (SIRT) as treatment for hepatic metastases of uveal melanoma: a Finnish nation-wide retrospective experience","volume":"57","author":"Tulokas","year":"2018","journal-title":"Acta Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib377","first-page":"3399","article-title":"Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites","volume":"43","author":"Tuomaala","year":"2002","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2022.101041_bib378","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.ajo.2003.09.009","article-title":"Conjunctival melanoma: is it increasing in the United States?","volume":"136","author":"Tuomaala","year":"2003","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib379","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1158\/1078-0432.CCR-08-0012","article-title":"Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma","volume":"14","author":"Ulmer","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib380","author":"US Food and Drug Administration"},{"key":"10.1016\/j.preteyeres.2022.101041_bib381","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/CMR.0000000000000129","article-title":"A retrospective analysis of 141 patients with liver metastases from uveal melanoma: a two-cohort study comparing transarterial chemoembolization with CPT-11 charged microbeads and historical treatments","volume":"25","author":"Valpione","year":"2015","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib382","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120181","article-title":"Development and external validation of a prognostic nomogram for metastatic uveal melanoma","volume":"10","author":"Valpione","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.preteyeres.2022.101041_bib383","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ophtha.2017.08.017","article-title":"Adjuvant sunitinib in high-risk patients with uveal melanoma: comparison with institutional controls","volume":"125","author":"Valsecchi","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib384","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jvir.2014.11.037","article-title":"Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases","volume":"26","author":"Valsecchi","year":"2015","journal-title":"J. Vasc. Intervent. Radiol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib385","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/0284186X.2016.1260773","article-title":"Anti-PD1 treatment in metastatic uveal melanoma in The Netherlands","volume":"56","author":"van der Kooij","year":"2017","journal-title":"Acta Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib386","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3390\/cancers11060845","article-title":"Uveal versus cutaneous melanoma; same origin, very distinct tumor types","volume":"11","author":"van der Kooij","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.preteyeres.2022.101041_bib387","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.ejso.2014.06.010","article-title":"Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study","volume":"40","author":"van Iersel","year":"2014","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib388","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1245\/s10434-008-9881-6","article-title":"Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases","volume":"15","author":"van Iersel","year":"2008","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib389","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ophtha.2017.12.022","article-title":"Genetic background of iris melanomas and iris melanocytic tumors of uncertain malignant potential","volume":"125","author":"van Poppelen","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib390","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi","volume":"457","author":"Van Raamsdonk","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.preteyeres.2022.101041_bib391","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in uveal melanoma","volume":"363","author":"Van Raamsdonk","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2022.101041_bib392","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1167\/iovs.17-22255","article-title":"PRiMeUM: a model for predicting risk of metastasis in uveal melanoma","volume":"58","author":"Vaquero-Garcia","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2022.101041_bib393","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/CMR.0b013e3283390365","article-title":"A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma","volume":"20","author":"Vihinen","year":"2010","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib394","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.ophtha.2007.01.032","article-title":"Incidence of uveal melanoma in Europe","volume":"114","author":"Virgili","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib395","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/CMR.0b013e32830317de","article-title":"Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients","volume":"18","author":"Voelter","year":"2008","journal-title":"Melanoma Res."},{"key":"10.1016\/j.preteyeres.2022.101041_bib396","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00432-006-0155-z","article-title":"Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival","volume":"133","author":"Vogl","year":"2007","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib397","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s00270-017-1588-2","article-title":"Percutaneous isolated hepatic perfusion as a treatment for isolated hepatic metastases of uveal melanoma: patient outcome and safety in a multi-centre study","volume":"40","author":"Vogl","year":"2017","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib398","series-title":"Interpretation of Diagnostic Tests","author":"Wallach","year":"2007"},{"key":"10.1016\/j.preteyeres.2022.101041_bib399","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.3747\/co.23.2859","article-title":"Management of uveal melanoma: a consensus-based provincial clinical practice guideline","volume":"23","author":"Weis","year":"2016","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib400","first-page":"1","article-title":"Cancer pain relief and palliative care. Report of a WHO expert committee. World health organ","volume":"804","year":"1990","journal-title":"Tech. Rep."},{"key":"10.1016\/j.preteyeres.2022.101041_bib401","series-title":"WHO Handbook for Reporting Results of Cancer Treatment","author":"World Health Organization","year":"1979"},{"key":"10.1016\/j.preteyeres.2022.101041_bib402","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000495113","article-title":"Uveal melanoma metastatic to the liver: treatment trends and outcomes","volume":"5","author":"Xu","year":"2019","journal-title":"Ocul. Oncol. Pathol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib403","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.1073\/pnas.1423021112","article-title":"Protein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer imaging","volume":"112","author":"Xue","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.preteyeres.2022.101041_bib404","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1148\/radiol.2521081252","article-title":"High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma","volume":"252","author":"Yamamoto","year":"2009","journal-title":"Radiology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib405","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S1499-3872(13)60095-8","article-title":"Treatment of liver metastases from uveal melanoma: a retrospective single-center analysis","volume":"12","author":"Yang","year":"2013","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"10.1016\/j.preteyeres.2022.101041_bib406","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2022.101041_bib407","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.ophtha.2016.01.023","article-title":"Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases","volume":"123","author":"Yavuzyigitoglu","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2022.101041_bib408","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1634\/theoncologist.2018-0233","article-title":"As long as you ask\": a qualitative study of biobanking consent-oncology patients' and health care professionals' attitudes, motivations, and experiences-the B-PPAE Study","volume":"24","author":"Yip","year":"2019","journal-title":"Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib409","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1200\/JCO.2008.19.7491","article-title":"Defining best supportive care","volume":"26","author":"Zafar","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib410","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/S1470-2045(11)70215-7","article-title":"Consensus-based standards for best supportive care in clinical trials in advanced cancer","volume":"13","author":"Zafar","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib411","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9510","article-title":"Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases: preliminary results of FOCUS (PHP-OCM-301\/301A) phase III trial","volume":"39","author":"Zager","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib412","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jvir.2018.04.030","article-title":"Combined effects of yttrium-90 transarterial radioembolization around immunotherapy for hepatic metastases from uveal melanoma: a preliminary retrospective case series","volume":"29","author":"Zheng","year":"2018","journal-title":"J. Vasc. Intervent. Radiol."},{"key":"10.1016\/j.preteyeres.2022.101041_bib413","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118564","article-title":"Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma","volume":"10","author":"Zimmer","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.preteyeres.2022.101041_bib414","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/bjo.62.6.420","article-title":"Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells","volume":"62","author":"Zimmerman","year":"1978","journal-title":"Br. J. Ophthalmol."}],"container-title":["Progress in Retinal and Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1350946222000015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1350946222000015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:41:57Z","timestamp":1777610517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1350946222000015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":413,"alternative-id":["S1350946222000015"],"URL":"https:\/\/doi.org\/10.1016\/j.preteyeres.2022.101041","relation":{},"ISSN":["1350-9462"],"issn-type":[{"value":"1350-9462","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metastatic uveal melanoma: The final frontier","name":"articletitle","label":"Article Title"},{"value":"Progress in Retinal and Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.preteyeres.2022.101041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101041"}}